Literature DB >> 15163166

Diagnosis and prognosis of breast and ovarian cancer--a population-based study of 234 women.

Hans O Thulesius1, Anna C Lindgren, Håkan L Olsson, Anders Håkansson.   

Abstract

The diagnosis and prognosis for 135 women with breast cancer and 99 women with ovarian cancer in a well-defined geographical area, and a follow-up of 7-15 years are described, based on patients' records. Diagnosis was initiated in primary care for 53% of women with breast cancer, and for 57% of women with ovarian cancer. Median patient delay was 1 week for breast cancer, and 3.5 weeks for ovarian cancer patients, and median provider delay was 3 weeks for both groups. Crude, relative, and corrected 5-year survival was 73%, 91%, and 82% in breast cancer, and 40%, 49%, and 43% in ovarian cancer. Cox multiple regression analyses showed that stage IIIA and IV, and young age were associated with impaired disease-related survival in breast cancer. In patients with ovarian cancer, stages III and IV at diagnosis, old age, and systemic symptoms dominating at presentation were predictive of reduced disease-related survival while a family history of cancer was predictive of increased survival.

Entities:  

Mesh:

Year:  2004        PMID: 15163166     DOI: 10.1080/02841860310022481

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

1.  The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro.

Authors:  Jing Jiang; Wei Chen; Rujin Zhuang; Tiefang Song; Peiling Li
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-17       Impact factor: 4.553

2.  Identifying suspected breast cancer: development and validation of a clinical prediction rule.

Authors:  Colin McCowan; Peter T Donnan; John Dewar; Alastair Thompson; Tom Fahey
Journal:  Br J Gen Pract       Date:  2011-05       Impact factor: 5.386

3.  Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS Patients: Cancer.

Authors:  V L Allgar; R D Neal
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

4.  Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.

Authors:  Aww Lim; D Mesher; A Gentry-Maharaj; N Balogun; M Widschwendter; I Jacobs; P Sasieni; U Menon
Journal:  BJOG       Date:  2015-05-29       Impact factor: 6.531

5.  Assessing how routes to diagnosis vary by the age of patients with cancer: a nationwide register-based cohort study in Denmark.

Authors:  B Danckert; H Jensen; N L Christensen; A Z Falborg; H Frederiksen; G Lyratzopoulos; S McPhail; A F Pedersen; J Ryg; L A Thomsen; P Vedsted
Journal:  BMC Cancer       Date:  2022-08-19       Impact factor: 4.638

6.  Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line.

Authors:  Yuh-Cheng Yang; Tsung-Chuan Ho; Show-Li Chen; Huei-Yi Lai; Ju-Yun Wu; Yeou-Ping Tsao
Journal:  BMC Cancer       Date:  2007-11-20       Impact factor: 4.430

7.  Patient and primary care delays in the diagnostic pathway of gynaecological cancers: a systematic review of influencing factors.

Authors:  Pauline Williams; Peter Murchie; Christine Bond
Journal:  Br J Gen Pract       Date:  2019-01-14       Impact factor: 5.386

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.